Sionna Therapeutics, Inc. Common Stock (SION)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 59
- Market Cap
- $2.1B
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
SentiSense also tracks daily options readings for Sionna Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Sionna Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.